Haemostatic effects of levothyroxine and selenomethionine in euthyroid patients with Hashimoto’s thyroiditis

Summary

The aim of this prospective study was to investigate for the first time whether levothyroxine and selenomethionine, administered alone or in combination, affect coagulation and fibrinolysis in Hashimoto’s thyroiditis patients with normal thyroid function tests. A group of 155 ambulatory women with recently diagnosed and previously untreated Hashimoto’s thyroiditis, of whom 149 completed the study, were randomly assigned in a double-blind fashion to six months of treatment with levothyroxine, selenomethionine, levothyroxine plus selenomethionine, or placebo. The control group included 39 matched healthy women. The prothrombin time ratio, the activated partial thromboplastin time, and plasma levels/activities of fibrinogen, factor VII, von Willebrand factor, factor X and plasminogen activator inhibitor-1 (PAI-1) were assessed at baseline and after three and six months of treatment. Compared with the healthy subjects, Hashimoto’s thyroiditis patients exhibited higher plasma levels/activities of all of the parameters studied, as well as were characterised by the abnormal prothrombin time ratio and activated partial thromboplastin time. All these haemostatic disturbances were reduced or normalised by levothyroxine + selenomethionine treatment, while the effect of levothyroxine or selenomethionine was limited to fibrinogen and PAI-1, respectively. Our results demonstrate that euthyroid women with Hashimoto’s thyroiditis are characterised by abnormal coagulation and fibrinolysis. Levothyroxine and selenomethionine, especially if administered together, produce a beneficial effect on haemostasis in euthyroid patients with this disorder.

Note: This study was in part a sub-study of another trial (ACTRN 12611000238976), which assessed the effect of levothyroxine and selenomethionine, administered alone or in combination, on monocyte and lymphocyte cytokine release in Hashimoto“s thyroiditis patients. Trial no.: ACTRN12612000271808.

Keywords

Hashimoto’s thyroiditis - levothyroxine - selenomethionine - coagulation - fibrinolysis - cardiovascular risk factors

• References

• 1 Weetman AP, McGregor AM. Autoimmune thyroid disease: developments in our understanding. Endocr Rev 1994; 15: 788-802.
• 2 Caturegli P. et al. Autoimmune thyroid diseases. Curr Opin Rheumatol 2007; 19: 44-48.
• 3 Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol 2010; 52: 151-156.
• 4 Owen PJ. et al. Thyroid disease and vascular function. Thyroid 2007; 17: 519-524.
• 5 Ciccone MM. et al. Increased carotid IMT in overweight and obese women affected by Hashimoto's thyroiditis: an adiposity and autoimmune linkage?. BMC Cardiovasc Disord 2010; 10: 22.
• 6 Stamatelopoulos KS. et al. Arterial stiffness but not intima-media thickness is increased in euthyroid patients with Hashimoto's thyroiditis: The effect of menopausal status. Thyroid 2009; 19: 857-862.
• 7 Krysiak R, Okopien B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2011; 96: 2206-2215.
• 8 Franchini M. et al. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009; 35: 288-294.
• 9 Vescovi PP. et al. The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost 2011; 37: 7-10.
• 10 Chan MY. et al. Hypercoagulable states in cardiovascular disease. Circulation 2008; 118: 2286-2297.
• 11 Warkentin TE. Haemostasis and atherosclerosis. Can J Cardiol 1995; 11 Suppl. C 29C-34C.
• 12 Kannel WB. Overview of haemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005; 40: 1215-1220.
• 13 Zaletel K, Gaberšcek S. Hashimoto's thyroiditis: from genes to the disease. Curr Genomics 2011; 12: 576-588.
• 14 Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430.
• 15 Levi M. et al. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60: 26-39.
• 16 Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007; 65: S253-S259.
• 17 Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-1632.
• 18 Asvold BO. et al. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med 2008; 168: 855-860.
• 19 Lekakis J. et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997; 7: 411-414.
• 20 Takamura N. et al. Thyroid function is associated with carotid intima-media thickness in euthyroid subjects. Atherosclerosis 2009; 204: e77-e81.
• 21 Asvold BO. et al. Association between blood pressure and serum TSH concentration within the reference range: a population-based study. J Clin Endocrinol Metab 2007; 92: 841-845.
• 22 Park HT. et al. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 2009; 62: 301-305.
• 23 Vanderpump MP. et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995; 43: 55-68.
• 24 Klapcinska B. et al. Selenium levels in blood of upper Silesian population: evidence of suboptimal selenium status in a significant percentage of the population. Biol Trace Elem Res 2005; 108: 1-15.